Selected Requirements of Prescribing Information

First Page		Document Content
Pharmaceutical sciences Pharmacology Medical terms Package insert Packaging Boxed warning Adverse effect Food and Drug Administration Medicine Health Pharmaceutical industry		Selected Requirements of Prescribing Information Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 183,41 KB Share Document on Facebook

	ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP 300 mg/15 mg Rx only BOXED WARNING WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROM DocID: 1uAsL - View Document
	synthesis levofloxacin coordination levofloxacin for septicemia levofloxacin and bcs levofloxacin urinary infection dosing. sulfamethoxazole susceptibility vs levofloxacin, levofloxacin ornidazole injection. levofloxacin DocID: 1qTvh - View Document
	News Previously published at www.cmaj.ca C DocID: 1q4jN - View Document
	synthesis levofloxacin amine copper cu complex, levofloxacin and renal adjustment synthesis levofloxacin coordination esomeprazole levofloxacin levofloxacin and pediatrics dose teva levofloxacin, levofloxacin for septice DocID: 1n5xt - View Document
	PERIKABIVEN® (amino acids, electrolytes, dextrose and lipid injectable emulsion), for intravenous use WARNING: DEATH IN PRETERM INFANTS See full prescribing information for complete boxed warning DocID: 1kdts - View Document